WaveMan
WaveMan · Company
LAB · Standard Biotools Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

LAB Standard Biotools (LAB) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001162194
Quote by TradingView
Activist 13D
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
87
13F, latest reported quarter

What the filings say about LAB

Activist stakes (13D), 180 days
1 filing
Largest: 15.0% of the class

Standard Biotools insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for STANDARD BIOTOOLS INC. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
Director
BUY
2025-12-04 SEC
150,000
$217.5K
-57.3%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Dec 3, 2025.
  • -24.3% median (-23.5% mean) 90-day return after 5 previous buys.
  • The trade is 0.2% of the 72,100,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought about $217.5K of LAB on Dec 4, 2025; 3 other insiders bought within 30 days and 87 funds added in the latest 13F quarter.
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
Director
BUY
2025-12-04 SECtraded 2025-12-03
75,000
$108.0K
-57.3%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Dec 2, 2025.
  • -23.4% median (-22.4% mean) 90-day return after 4 previous buys.
  • The trade is 0.1% of the 71,950,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought about $108.0K of LAB on Dec 3, 2025; 3 other insiders bought within 30 days and 87 funds added in the latest 13F quarter.
CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
Director
BUY
2025-12-04 SECtraded 2025-12-02
125,000
$177.5K
-57.3%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 26, 2024.
  • -24.3% median (-22.4% mean) 90-day return after 3 previous buys.
  • The trade is 0.2% of the 71,875,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought about $177.5K of LAB on Dec 2, 2025; 3 other insiders bought within 30 days and 87 funds added in the latest 13F quarter.
Casdin Partners GP, LLC
Director
BUY
2025-11-26 SECtraded 2025-11-25
7,550,000
$9.8M
-59.3%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Nov 24, 2025.
  • -8.4% median (-9.2% mean) 90-day return after 8 previous buys.
  • The trade is 10.5% of the 71,750,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Casdin Partners GP, LLC bought about $9.8M of LAB on Nov 25, 2025, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 87 funds added in the latest 13F quarter.
Casdin Partners GP, LLC
Director
BUY
2025-11-26 SECtraded 2025-11-24
150,000
$214.5K
-59.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Nov 12, 2025.
  • +5.1% median (-7.4% mean) 90-day return after 7 previous buys.
  • The trade is 0.2% of the 64,200,000 shares held after it.
  • 3 other insiders bought within 30 days.
  • 87 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Casdin Partners GP, LLC bought about $214.5K of LAB on Nov 24, 2025; 3 other insiders bought within 30 days and 87 funds added in the latest 13F quarter.
84 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 79 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
87 funds bought in last quarter
more than 63% of Pharma & Biotech
Revenue
-6.2% year over year
below 63% of Pharma & Biotech
Margin
-87.8% net margin
below 56% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
1.4% of the float short (float per yahoo 2026-10-26) · 2.7 days to cover · settled 2026-09-30
below 77% of Pharma & Biotech
The situation: each line is one rule over one dataset
VIKING GLOBAL INVESTORS LP disclosed a 5%+ stake (15.0%) in the last six months.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch LAB

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-53.8%12M
-54%-27%+0%+27%2025-102025-122026-022026-042026-062026-082026-10 2025-11-25 · Casdin Partners GP, LLC bought $9.8M2025-11-20 · Casdin Eli bought $585.0K2025-11-13 · Casdin Partners Master Fund, L.P. bought $540.0K2025-11-19 · Casdin Eli bought $448.0K2025-11-12 · Casdin Partners GP, LLC bought $446.2K2025-11-11 · Casdin Partners GP, LLC bought $360.0K2025-11-18 · Casdin Eli bought $338.2K2025-11-10 · Casdin Partners GP, LLC bought $321.8K2025-11-14 · Casdin Partners Master Fund, L.P. bought $310.0K2025-11-17 · Casdin Partners Master Fund, L.P. bought $274.5K2025-11-07 · Casdin Partners GP, LLC bought $252.0K2025-12-04 · CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought $217.5K2025-11-24 · Casdin Partners GP, LLC bought $214.5K2025-12-02 · CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought $177.5K2025-12-03 · CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC bought $108.0K2026-06-12 · VIKING GLOBAL INVESTORS LP filed a 5%+ stake (15.0%)2026-06-12 · Viking Global Opportunities Parent GP LLC filed a 5%+ stake (15.0%)2026-06-12 · Viking Global Opportunities GP LLC filed a 5%+ stake (10.1%)2026-06-12 · Viking Global Opportunities Portfolio GP LLC filed a 5%+ stake (10.1%)2026-06-12 · Viking Global Opportunities Illiquid Investments Sub-Master LP filed a 5%+ stake (10.1%)2026-06-12 · Viking Global Opportunities Drawdown GP LLC filed a 5%+ stake (5.0%)2026-06-12 · Viking Global Opportunities Drawdown Portfolio GP LLC filed a 5%+ stake (5.0%)2026-06-12 · Viking Global Opportunities Drawdown (Aggregator) LP filed a 5%+ stake (5.0%)2026-06-12 · HALVORSEN OLE ANDREAS filed a 5%+ stake (15.0%)2026-06-12 · Shabet Rose Sharon filed a 5%+ stake (15.0%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns LAB: institutional holders (13F)

13F holdings, latest reported quarter
Casdin Capital, LLC
88,783,856 sh
$73.0M
VIKING GLOBAL INVESTORS LP
58,651,170 sh
$48.3M
MAK CAPITAL ONE LLC
28,813,904 sh
$23.7M
Long Focus Capital Management, LLC
23,500,000 sh
$19.3M
VANGUARD CAPITAL MANAGEMENT LLC
12,252,998 sh
$10.1M

Congress trades in LAB

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
VIKING GLOBAL INVESTORS LP
Activist 13D · 2026-06-12
15.0%
Viking Global Opportunities Parent GP LLC
Activist 13D · 2026-06-12
15.0%
Viking Global Opportunities GP LLC
Activist 13D · 2026-06-12
10.1%
Viking Global Opportunities Portfolio GP LLC
Activist 13D · 2026-06-12
10.1%
Viking Global Opportunities Illiquid Investments Sub-Master LP
Activist 13D · 2026-06-12
10.1%

LAB planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

LAB mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$78.2K position · as of 2026-05-31
0.4%
Global X Genomics & Biotechnology ETF
$196.4K position · as of 2026-05-31
0.4%
Royce Micro-Cap Fund
$1.0M position · as of 2026-06-30
0.2%
Royce Capital Fund - Micro-Cap Portfolio
$334.3K position · as of 2026-06-30
0.2%
Inception Portfolio
$538.8K position · as of 2026-06-30
0.2%
EQ/Morgan Stanley Small Cap Growth Portfolio
$414.2K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
An activist crossed the 5% line with declared intent.
The record shows 87 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

LAB financials

Revenue growth
-6.2%
XBRL, annual
Net margin
-87.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Net margin, TTM
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Free cash flow, TTM
-$82.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-268.56x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
+17.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+14.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-18.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
2.77x
close 2026-10-23 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
-$30.3M
market value at close 2026-10-23 on 2026-08-03 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-34.5%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$85.3M$174.4M$106.3M$97.9M
Gross profit$42.5M$44.9M$50.5M$37.1M
Operating income-$110.2M-$127.5M-$76.6M-$116.2M
Net income-$74.9M-$138.9M-$74.7M-$190.1M
EPS (diluted)-0.20-0.52-0.94-2.43
Operating cash flow-$74.3M-$143.5M-$43.3M-$89.4M
Cash$120.9M$166.7M$51.7M$81.3M
Long-term debt$299.0K$299.0K$63.5M$64.9M
Buybacks$0$40.5M$5.4M$563.0K
SEC XBRL, fiscal years, as known on 2026-10-27

LAB Stock Sonar score 5/7 axes

Find similar shapesCompare

LAB ranks highest on profitability (84th percentile) and risk and compliance (67th), and lowest on growth (39th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
84
Inputs
  • Return on equity+17.6% · 88 pct, sector of 545
  • Return on assets+14.3% · 91 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-18.5% · 74 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.00x · 86 pct, sector of 352
  • Cash flow to debt-268.56x · 5 pct, sector of 371
Growth
39
Inputs
  • Revenue growth, YoY-6.2% · 37 pct, sector of 505
  • Backlog growth, YoY-13.0% · 41 pct, sector of 40
Institutional and government
63
Inputs
  • Funds adding, latest quarter87 · 63 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
67
Inputs
  • Short interest, % of float+1.4% · 78 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+9.3% · 57 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

LAB filings, in plain words

Read the full summary

1 activist Schedule 13D filing in the last 180 days declared an intent to influence the company, the largest for 15.0% of the class. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies